TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07284797: A Phase 1, First-in-Human, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of XmAb657 in Healthy Participants and in Participants With Autoimmune Diseases

Sponsor: Xencor, Inc. · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 60 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,507,200

Rescue Site Savings

+$4,950,060

Unlock Full NCT07284797 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07284797 Rescue Dossier →